In This Issue:

Letter from the President
Preview of the 2023 Annual Meeting
Program Chair Update on 2023 Meeting
2023 Awards for Excellence
In Memoriam
2023 Travel Award Recipients
Membership Spotlight
Drug and Alcohol Dependence Editor's Picks
Drug and Alcohol Dependence Journal Corner
CPDD's Committee Reports
CPDD EXECUTIVE COMMITTEE

President
Amy C. Janes, Ph.D.

President-Elect
Deborah Hasin, Ph.D.

Treasurer
Jack Bergman, Ph.D.

Past-President
William Stoops, Ph.D.

Public Policy Officer
Sandra Comer, Ph.D.

CPDD BOARD OF DIRECTORS
Sudie Back, Ph.D.
Jack Bergman, Ph.D.
Qiana Brown, M.P.H., M.S.W., Ph.D., LCSW
Sandra Comer, Ph.D.
Kelly Dunn, M.B.A., Ph.D.
Francesca Filbey, Ph.D.
Albert Garcia-Romeu, M.A., Ph.D.
Cassandra Gipson-Reichardt, Ph.D.
Angela Heads, Ph.D.
Jermaine Jones, Ph.D.
Wendy Lynch, Ph.D.
Silvia Martins, M.D.
Angela Moreland, Ph.D.
Marco Pravetoni, Ph.D.
James Rowlett, Ph.D.
Dace Svikis, Ph.D.
Michael Taffe, Ph.D.
Erin Winstanley, Ph.D.

CPDD EX OFFICIO

Rules Chair
Charles Gorodetzky, M.D., Ph.D.

Executive Officer
Jesse Howard

EDITORS
Maria Parker, M.P.H., M.S., Ph.D.

CPDD COMMUNICATIONS COMMITTEE
Bethea (Annie) Kleykamp, Ph.D. Chair
Daniel Fuster, M.D., Ph.D.
Rachel Gicquelais, M.P.H., Ph.D.
Jodi Gilman, Ph.D.
Jillian Hardee, Ph.D.
Barrett Montgomery, B.S.
Jacques Nguyen, Ph.D.
Maria Parker, M.P.H., M.S., Ph.D.
Tasha Perdue, Ph.D.
Frank Schwebel, Ph.D.

Want to contribute or advertise in Newsline? Email info@cpdd.org
Dear friends and colleagues,

The 2023 Annual Meeting is just around the corner, and I am beyond excited for you to find out everything we have in store. This year’s meeting will bring some exciting changes as we return for our second in-person meeting since the start of the COVID pandemic. I think these positive changes allow us to showcase stellar science and help CPDD be a more inclusive meeting and society for all of our attendees from across the globe.

This year marks our 85th CPDD Annual Scientific Meeting and we celebrated our 94th birthday. I’d like to express my deepest gratitude to all of our CPDD committee members, the Board of Directors, the Executive Committee and our Parthenon management group (PMG) team who have worked tirelessly to make sure our scientific community continues to grow and thrive despite all of the challenges over the past years.

In second half of 2022, we announced significant change to the membership application process. New applicants no longer need to search for CPDD members to write a letter of recommendation for membership. Thanks to this change, over 200 new member applications have been received since November 2022, many of whom are senior scientists and early career investigators. We also announced countries identified as lower- and lower-middle income by the World Bank now receive complimentary membership as do Members-In-Training who received a Pell Grant during their undergraduate degree. Membership applications are now reviewed monthly to expedite the process, plus Members-In-Training can extend their status for three year’s post terminal degree and up to five years by special request. We commend the Membership Committee and Board of Directors for making these significant changes that will only strengthen our community. CPDD now has over 1,000 members and is still growing.

The annual meeting received 999 Symposium, Mini-Symposium, Forum, Workshop, and Poster submissions. I would like thank Dr. Kevin Freeman and the entire Program Committee for their hard work and tenacity planning this year’s meeting. This year, all attendees can look forward to sessions of interest to CPDD’s scientifically diverse membership, including medicinal chemists, preclinical researchers, human laboratory researchers, clinicians, epidemiologists, clinical researchers. There’s also a special track for early career members! CPDD continues to partner with ISGIDAR to produce their Annual Meeting on Saturday, June 10. NDEWS, RAMS and the InWomen’s conference will also be held in conjunction with CPDD this year. The pandemic has put a slight damper on this year’s meeting as the NIDA International Forum and the NIDA Early Career (formerly Grant Writing) Workshop will take place virtually. We hope they will be able to join us again in-person next year in Montreal.

I also want to highlight this year’s Presidential Symposium, which is entitled The case against purity: studying the intersection of psychiatric and substance use disorders. The keynote speakers will be: Dr. Eden Evins from Harvard Medical School and Dr. Jibran Khokar from the University of Western Ontario. While both speakers will discuss research on co-morbid mental health and substance use disorders, they bring distinct, complementary perspectives. Dr. Evins is a psychiatrist and director of the Center of Addiction Medicine at Massachusetts General Hospital. She has conducted clinical research ranging from large multi-center clinical trials to smaller laboratory-based studies aimed at understanding neurobiological elements underlying substance use including in those with mental health issues such as schizophrenia. Dr. Khokar is an Associate Professor and director of the neurobiology of dual disorders
laboratory. He uses preclinical behavioral, genetic, electrophysiological, and neuroimaging techniques to understand mechanisms underlying co-occurring serious mental illness and substance use disorders. After presenting, our keynote speakers will be joined by Drs. Margaret Haney, George Koob and Nora Volkow for a discussion where audience questions are encouraged! Don’t forget, you can still register for the meeting without having to register onsite. To register, click here. You can also contact the Executive Officer any questions via email at info@cpdd.org or by calling 615.432.0099.

I am also excited to announce six highly deserving recipients of our Award for Excellence this year.

- Nathan B Eddy Memorial Award: Edythe London, University of California Los Angeles
- Mary Jeanne Kreek Underserved Populations Award: Denise Hien, Rutgers, The State University of New Jersey
- CPDD Mentorship Award: Dace Svikis, PhD, Virginia Commonwealth University
- Joseph Cochin Young Investigator Award: Justin Strickland, PhD, Johns Hopkins University School of Medicine
- Marian W. Fischman Lectureship Award: Joy Schmitz, University of Texas Health Science Center
- Martin and Toby Adler Distinguished Service Award: Jack Bergman, PhD, Mclean Hospital, Harvard University

Please join us at the new Awards Dinner and Dancing (which some fondly refer to as Prom) as we celebrate each of their contributions to substance use disorder research and cap the night off with performances by Elevation Band.

CPDD also provided 81 Travel Awards for the 2022 Annual Meeting. Congratulations on to all of our recipients. You can review the entire list here.

Lastly, please don’t forget to renew your membership! CPDD membership and conference registrations directly fund our numerous programs, our new early career investigator grant, awards, and numerous opportunities for early career scientists. We are continuing to define ways CPDD can better support all of our members. To meet this goal, we recently formed a mentoring task force and an LGBTQIA+ task force. To ensure that we continue advancing substance use disorder research and support new initiatives such as these, I encourage you to renew your membership if you haven't already.

I look forward to seeing the brightest minds in our community and your amazing science at our June Annual Meeting!

Healthy regards,

Amy Janes, PhD
CPDD President
CPDD provides a national and international forum for scientists of diverse backgrounds to advance the understanding of molecular-neurobiological aspects of addictive disorders and, by the application of new scientific knowledge, to improve and develop treatments utilizing novel behavioral and pharmacological therapies.

Since 1938, a major focus of the CPDD’s activities has been its sponsorship of an annual scientific meeting. This conference serves as a forum bringing together basic scientists and clinical investigators from industry, academia, and government. Representatives of regulatory agencies, as well as scientists and professionals in a number of diverse disciplines interested in the biochemical, behavioral, and public health aspects of drug dependence, participate. We expect to have more than 1,000 attendees for the 2023 meeting, including many international attendees who come for the CPDD meeting as well as the NIDA International Forum. This year’s meeting also boasts the NIDA Early Career Workshop and the SBIR Poster Session.

The meeting will feature more than 600 learning and engagement opportunities, including Symposiums, Mini-Symposiums, Forums, Workshops, Posters, and Oral Presentations. Here is a preview of what you can expect.

**Beyond GWAS: The Genetics and Epigenetics of Addiction**
Chair: Jonathan Pollock, PhD
Co-Chair: Arpana Agrawal, PhD

GWAS studies are rapidly identifying variants underlying addiction and complex psychiatric disorders. These variants are being found within the coding regions of genes and in non-coding regions of the genome. Understanding how these different types of variants contribute to addiction and behaviors associated with addiction requires approaches that identify functional consequences, assess gene x gene interactions within gene networks, and creation of addiction risk scores associated with these variants. In this symposium, we will discuss technologies that uncover the underlying biology of GWAS variants using four different approaches: identifying function through analysis of variant-specific chromatin changes, using big data to identify gene x gene interactions and gene networks, analysis of short tandem repeats, and assessing addiction risk in the context of complex psychiatric disorders.

**Development of Fentanyl-Targeted Vaccines to Decrease Overdose Fatalities**
Chair: Drew Townsend, PhD
Co-Chair: Jason Sousa, PhD

The aims of this symposium include 1) educating the audience on the mechanisms of the leading anti-opioid vaccination strategies, 2) provide the current state of the science of opioid-targeted vaccines, and 3) discuss practical considerations of opioid vaccine development. These goals will be accomplished by highlighting three approaches for vaccination under preclinical consideration and conclude with a preview of how these vaccines may be tested under human-laboratory conditions. The first speaker will share findings with a fentanyl-conjugated vaccine, a conventional and well-established approach for vaccination. The second speaker will share findings with a monoclonal vaccination approach for fentanyl.
Driving Impairment Caused by the Use of Cannabis and Other Drugs: Recent Evidence from Human Laboratory Studies
Chair: Tory Spindle, PhD
Co-Chair: Carlos Zamarripa, PhD

This symposium will include some of the most recent human laboratory research on driving impairment caused by cannabis, which is a growing public health concern. Specific topics discussed will include impairment from novel routes of cannabis administration (e.g., edibles), individual differences in impairment, and novel approaches to detecting impairment among drivers under the influence of cannabis.

Dysregulation of the Prefrontal Cortex in Substance Use Disorders
Chair: Jacqueline McGinty, PhD
Co-Chair: Kathryn Cunningham, PhD

Dysregulation of the medial prefrontal cortex (mPFC) during substance use disorders (SUDs) is a major characteristic of relapse to drug seeking and the cognitive deficits that accompany relapse. However, we know little about the phenotypes that result from structure and functional mPFC deficits in impulse control and executive decision-making during SUD development. In this symposium, a diverse panel of investigators who represent multi-disciplinary perspectives will address recent evidence indicating that substance use (a) engages the mPFC in complex neurocircuitry that is helping to guide precise diagnoses and make therapeutic decisions in SUDs, (b) disrupts the regulation of mPFC pyramidal neurons by fast-spiking, parvalbumin (PV)-expressing interneurons and the perineuronal nets (PNNs) surrounding them, and (c) by engaging mPFC circuitry, serotonin target-phenotype relationships precipitate SUD risk. Altogether this panel will highlight the importance of the relationship between specific PFC neuronal subpopulations in preclinical and clinical models that expand our understanding of clinical phenotypes of SUDs.

The Intersection of Aging, Tobacco Use, and Health Equity
Chair: Bethea Kleykamp, PhD

Over the last 20-plus years, combustible cigarette prevalence has dropped to the lowest levels ever recorded for young people in the United States but has not changed for older adults (65 years+). Many people who smoke into later decades of life have been historically minoritized, including individuals who are Black and Hispanic, have a lower socioeconomic status, and/or have more chronic health issues. Thus, aging and tobacco use is a long-standing health equity issue that continues to be overlooked in research, treatment, and policy. Our symposium will address four different tobacco products/policy initiatives, including 1) very low nicotine content cigarettes, 2) electronic cigarettes, 3) menthol and non-menthol tobacco flavoring, and 4) lung cancer screening. Given this symposium’s broad focus, we expect it will be of great interest to clinical researchers, healthcare providers, and health policy organizations that seek to learn about tobacco-related disparities among older adults.
The Intersection of COVID-19 and Substance Use Disorders
Chair: Carlos Blanco, MD, PhD
Co-Chair: Leonardo Angelone, PhD

This symposium will present a variety of epidemiological and health services responses to the intersection of COVID-19 and substance use disorders. Dr. Ramsey will present an overview of changes in overdose deaths in New York State during COVID-19, innovative practices in the delivery of SUD treatment services during that period, and lessons learned for the future. Dr. Halden will discuss the use of waste-water based epidemiology to monitor community levels of SARS-CoV-2 as well as opioids, as well as opportunities and limits of information gleaned from the waste-water analysis. Dr. Jones will discuss a series of analyses examining use of telehealth for opioid use disorder prior to and during the COVID-19 pandemic among the Medicare population. The analyses explore use of telehealth services and impacts on receipt of medications for opioid use disorder (MOUD), MOUD retention, experiencing medically treated overdose, and overdose death.

There will be a discussion among all panelists regarding changes in Federal- and state-level legislation and regulations, innovations to increase access to MOUD, approaches to workforce support and augmentation and innovations to increase access to overdose prevention, such as naloxone distribution, syringe services programs, drug checking, and overdose prevention centers.

Throughout the symposium, there will be multiple opportunities for interaction with the audience to ensure that the approach is participative and inclusive, rather than adopting a top-down didactic approach.

The Potential of Psychedelic Therapies for Substance Use Disorders
Chair: Albert Garcia-Romeu, MA, PhD

Historically, clinical research with classic psychedelics such as LSD focused heavily on applications treating substance use disorders (SUDs). Meta-analysis of early controlled trials comparing LSD to non-psychedelic control conditions found a single high-dose LSD treatment was associated with significantly greater reductions in alcohol misuse than control. Similarly, a preliminary trial of high-dose LSD with residential treatment in formerly incarcerated men with a history of opioid dependence found significantly greater biologically verified opioid abstinence in the LSD vs. treatment-as-usual control condition up to 12 months post-treatment. These studies and anecdotal and observational reports on indigenous and naturalistic psychedelic use formed the basis for novel research on psychedelic therapies for SUD in the 21st century, with small preliminary trials of psilocybin and ayahuasca for various SUDs showing feasibility and promise. More recently, larger randomized controlled trials of psilocybin for SUD have been conducted. Published data from a placebo-controlled trial in patients with alcohol use disorder showed significantly greater reductions in heavy drinking days and daily alcohol consumption after two high doses of psilocybin with motivational enhancement therapy (MET) compared to placebo with MET.

Available data from recently completed controlled trials of psilocybin-assisted treatment for tobacco and cocaine use disorder will also be discussed. Additionally, growing preclinical research is probing biological activity underlying psychedelics’ anti-addictive effects. These findings will be examined in the context of investigating psychedelic therapies and their mechanisms, and exploring the ramifications for potential psychedelic-assisted treatments for SUD.
Fentanyl was developed medicinally to be different from other opioid agonists and illicitly manufactured fentanyl is now presenting unique challenges to the treatment community. This session will review fentanyl's unique pharmacodynamic profile, its secondary peaking pattern, fentanyl-induced vocal cord (glottic) closures (contributing to overdose deaths), and present descriptions of how withdrawal from fentanyl differs from other opioids in patient's own words. The goal of this session is to inform the scientific community of these unique features to spur innovation in fentanyl-treatment.

People who use drugs (PWUD) are disproportionately affected by the HIV epidemic. Many PWUD do not benefit from highly efficacious HIV prevention and treatment interventions, such as pre-exposure prophylaxis and antiretroviral therapies. In this symposium, speakers will present progress being made in the development of integrated interventions, encompassing a range of substances of abuse, treatment delivery modalities, and affected populations.

Advances in behavioral economic research have culminated in the development of a novel conceptual framework – Reinforcer Pathology Theory. Reinforcer Pathology Theory posits that reinforcers are integrated over a temporal window that determines the relative value of drugs and prosocial alternatives such that brief, immediate, intense, and reliable reinforcers (e.g., substance use) are overvalued compared to alternatives lower in their intensity, variable in their outcome, and delayed in their value accumulation (e.g., employment). This session will trace the past, present, and future of Reinforcer Pathology Theory using data from diverse drug classes and from preclinical, human laboratory, and clinical settings.
Neuropeptides in Reward, Addiction, and Mental Health (Symposium)
Chair: Sam Ananthan, PhD
Co-Chair: Lakshmi Devi, PhD

Neuropeptides play a central role in physiological and pathological processes relating to reward, learning, memory, stress, addiction, and neurological disorders. Recent studies have revealed the prevalence and role of a spectrum of neuropeptides in modulating neural activity and behavioral functions. These findings, in addition to illuminating the biological role of the neuropeptides, are revealing the potential of targeting the neuropeptide/receptor systems for the development of therapeutics for the treatment of neurobehavioral disorders. In this symposium, Dr. Jessica Barson from Drexel University College of Medicine will discuss the role of pituitary adenylate cyclase-activating polypeptide (PACAP) in binge-like ethanol drinking and affective behavior, Dr. William Giardino from Stanford University will discuss neuropeptide circuitry in the extended amygdala and its role in emotional arousal, and Dr. Lakshmi Devi from Icahn School of Medicine at Mount Sinai will highlight the intricacies of signaling by endogenous opioid peptides and novel neuropeptides in pain, addiction, and mental health.

The Racist Origins and Impact of the War on Drugs: Changing our Perspective of Illicit Drug Misuse from Criminal Behavior to a Public Health Issue
Chair: Bryon Adinoff, MD
Co-Chair: Brenda Curtis, MPH, PhD

The Black Lives Matter (BLM) movement has raised awareness of the systemic racism embedded in the laws, institutions, and culture of the U.S. A key driver of systemic racism is the War on Drugs. Most U.S. drug laws were promoted to the public using racist arguments and have been used to disenfranchise and incarcerate millions of individuals, particularly people of color. Consequences include arrests, incarcerations, violent policing, and the lifelong effects of an arrest/prison record upon education, employment, housing, and child custody. The criminal consequences of illicit drug use make our field of medicine unique in that suffering from an addictive illness (e.g. opioid use disorder) is punishable by law, even in the absence of harm. Moreover, criminal punishment can also exacerbate mental illness and contribute to problematic drug use. Nevertheless, addiction-related medical and research organizations by and large continue to either support drug prohibition or remain silent. In this symposium, the speakers will provide an overview of the origins and impact of drug prohibition, the centrality of race and stigma to the prohibitionist structure, and the role of the addiction research community in resolving the inherent conflict between substance use as a criminal behavior vs. biologic illness. A moderated discussion will allow audience input into the role the CPDD community can play to re-orient society’s focus on drug prohibition to evidence-based drug treatment, where appropriate.
A Preview of the 2023 Annual Meeting

Treating SUD in Patients with PTSD and Histories of Victimization
Chair: Carrie Mulford, PhD
Co-Chair: Katherine Mills, PhD

PTSD and SUD commonly co-occur, with approximately 30% of youth and 50% of adults with PTSD also meeting criteria for SUD. Traumatic experiences are risk factors for the development of SUD. Moreover, the co-occurrence of PTSD and SUD is associated with more severe symptoms and worse clinical outcomes. This panel will present research demonstrating that integrated treatment of comorbid PTSD and SUD, is feasible and effective in reducing symptoms of both disorders.

Using Big Data to Understand the Role of the Gut Microbiome in Substance Use Disorders
Chair: Susan Wright, PhD
Co-Chair: Kiran Vemuri, PhD

Substance use disorders (SUDs) are known to co-occur at high prevalence with other mental health disorders and can involve several different substances, including cocaine, methamphetamine, opioids, cannabinoids, nicotine, and alcohol. While much SUD research has focused on the neurologic and genetic components of usage behavior, there is increasing interest in the role of the gut microbiome in the pathogenesis of SUD. With the continuous collection of large volumes of various data types, researchers are trying to facilitate microbiome research by building large reference data sets to serve as a foundation for new technologies and data analysis tools. This symposium will feature four speakers and will explore current research providing evidence that the gut microbiome is involved in SUDs and the challenges and opportunities for understanding the role of the microbiome in health. Dr. Jason Bubier (The Jackson Laboratory) will describe the relationships between the gut microbiome and various addiction or addiction-related behaviors in diverse mice. Dr. Yanjiao Zhou (University of Connecticut Health Center) will present her work on the gut microbiome in influencing binge drinking and efficacy of pharmacological interventions of alcohol use disorder. Dr. Drew Kiraly (Wake Forest University School of Medicine) will present data from his lab on utilizing metagenomics, metabolomics, and proteomics analysis to

Stimulation for the Treatment of Stimulant Use Disorder
Chair: Katrina Foster, PhD
Co-Chair: Jennifer Wong

The symposium, Stimulating the Brain to Treat Stimulant Use Disorder (StUD), will examine the role of neuromodulation in the management of StUD and stimulant craving. Currently, there are no FDA approved treatments for the management of StUD. This symposium provides an opportunity for the NIDA portfolio on neuromodulation for the treatment of StUD and stimulant craving to be presented. Dr. Nassima Ait-Daoud from the University of Virginia will present her research on LIFU for the treatment of cocaine use disorder, Dr. Joseph Sakai at the University of Denver- Colorado will present his data on DBS for treatment refractory methamphetamine use disorder, Dr. Datta from Soterix will present his research on Transcranial Direct Stimulation (tDCS) for reducing cocaine craving and Dr. Pamela D. Scott from the FDA Device Regulatory Division will describe the approval process for Devices.
Considerable progress in understanding substance use disorders has been made using animal models. This symposium will highlight the profound contributions of such research and its translational impact made by one of CPDD’s long-time members, Bill Woolverton, on the 10th anniversary of his passing. Bill was passionate about rigorous experimental designs using operant procedures, with a focus on translating these preclinical findings to clinical applications. Dr. Nader will discuss the use of concurrent food-drug schedules of reinforcement to model vulnerability to substance misuse, which began for Bill during the late 1980's and while at the University of Chicago, and how these models can inform interpretations of reinforcing strength and intervention strategies involving polysubstance use. Dr. Rowlett will explore mechanisms of reinforcement and how they tie into, or are explained by, other pharmacological effects engendered by drugs using examples from his research using nonhuman primates, which originated after joining the Bill Woolverton Band (1993-1997) at the University of Mississippi Medical Center. Dr. Freeman will discuss the study of drugs as punishers and the translational implications of Bill’s efforts for the development of abuse-deterrent formulations for prescription drugs. Bill had a deep appreciation for the powerful role of the environment, and Dr. Huskinson will discuss environmental determinants of drug vs. nondrug choice, including delay and variable schedules of reinforcement. The session will conclude with moderated discussion of and reflection on Bill’s substantial legacy and the growth opportunities stemming from his impressive body of work.

Beyond the Dichotomy: Understanding Disparities in Cannabis Use Behaviors Across LGBTN+ Subgroups of Adolescents & Young Adults
Chair: Cara Struble, PhD
Co-Chair: Jessica Barrington-Trimis, PhD

Cannabis use and cannabis-related problems remain highly prevalent among adolescents and young adults (AYA), particularly among those who identify as belonging to a sexual identity minority (lesbian, gay, bisexual, etc. [LGB+]) or gender identity minority (transgender, non-binary, etc. [TN+]) (collectively, LGBTN+). Research has routinely failed to capture heterogeneity in cannabis use behaviors across the diverse range of LGBTN+ identities. This mini-symposium will highlight the need for scientists to expand analyses to explore differences in cannabis use behaviors within the LGBTN+ population. Talks will examine key individual, interpersonal, and structural mechanisms that may explain observed disparities within and outside the LGBTN+ population of AYA. This collection of presentations on LGBTN+ disparities in cannabis use behaviors will discuss implications for future research, treatment, and policy, providing concrete suggestions for research strategies to better understand disparities in substance use behaviors for the LGBTN+ population.
Nothing About Us Without Us: Engaging Individuals with Lived Experience of Substance Use Disorders in Substance Use Research Development and Implementation
Chair: Omayma Alshaarwy, PhD
Co-Chair: Rachel Luba, PhD

Involving individuals with lived experience of substance use disorders (LESUD) in research is increasingly recognized as a critical strategy to reduce stigma, develop effective personalized interventions, and enhance policy recommendations. The College of Problems on Drug Dependence Human Research Committee presents a forum focusing on guiding principles to ensure purposeful engagement of individuals with LESUD in research. The forum will provide attendees with different perspectives and best practices to collaborate with individuals with LESUD to design effective and responsive research programs and enhance clinical practice and public policy.

Restructuring the Pathway from Discovery to Dissemination of New Medications in the Academic Environment
Chair: Charles France, PhD
Co-Chair: Jennifer Potter, MPH, PHD

This forum will address the challenges faced by investigators, especially those in academia, in advancing basic science discoveries that have the potential to improve treatment of substance use disorders to patients. Historically, dissemination and implementation of treatments for substance use disorders have been inefficient and ineffective (e.g., buprenorphine), despite clear evidence that medications can be effective for treating substance use disorders and that with comprehensive care recovery is achievable. This forum will discuss the potential value of bidirectional translational conversations across the spectrum of stakeholders, from drug discovery to patients, early and throughout the process of medication development, and from community-oriented solutions back to basic scientists to identify mechanisms of action. Examples of current research will highlight how early engagement of implementation and dissemination research can accelerate the manner by which drugs for treating SUD become available as treatment options.
Greetings CPDD colleagues,

We are thrilled to be able to welcome you to the 2023 meeting in Denver, Colorado. We have an exciting program to share with you. There are an array of invited sessions on the slate including symposia focused on the science of fentanyl as an atypical opioid, psychedelics as therapeutics for SUDs, and interactions between COVID and SUDs. There will also be an invited workshop focusing on the construct of Preaddiction, which will be chaired by Dr. Nora Volkow with Drs. George Koob and Tom McLellan joining as speakers. In addition, we will celebrate the lives and professional contributions of two of CPDD's most storied members, Drs. Martin “Marty” Adler and Mary Jeanne Kreek, with oral sessions hosted by their former trainees and close colleagues. Lastly, we had one of the highest abstract-submission numbers on record for CPDD, which will bring a lot of great content to the 2023 meeting.

Some features that were introduced at last year’s meeting will continue this year. First, we will continue our collaboration with the NIDA OTIPI office to highlight work from the institute’s small-business portfolio with a special poster session showcasing the cutting-edge work supported by NIDA’s SBIR/STTR program. We will have over 40 posters for this session, so be sure to attend and learn about the many innovations and technologies emerging in our field. Also, we will offer structured sessions for members to schedule and meet with NIDA program officials who are attending the meeting (stay tuned for an announcement about scheduling and the participating officials). In addition, we will continue with the 1-hour programming blocks for the oral sessions. The introduction of this change last year was met with great enthusiasm, and we will once again be able to enhance the breadth of our content with this "punchier" format.

Long-standing traditions of our meeting will also continue. We will have our customary plenary and presidential sessions, two late-breaking sessions, our standard forums, and our networking sessions including the Brunch with Champions. However, the real icing on the cake of tradition will be…drum roll please…the return of dinner and dancing, now known as the Awards Dinner Celebration! That's right. Prom is back! Don't forget your finery. We will add a twist this year by combining our awards presentations with the dinner event, so please be sure to attend to support our fabulous awardees. This year's event will also feature live music from Elevation Band!

Lastly, I want to thank the members of the Program Committee for their excellent work and their commitment to CPDD. Each member contributed many hours of effort to review submissions and develop the 2023 program. I am honored to serve with this fantastic group.

See you all in Denver!

Kevin Freeman, Ph.D.
Chair, Program Committee
The College on Problems of Drug Dependence

85th Annual Meeting
DENVER, CO │ June 17 - 21, 2023

Registration is OPEN
REGISTER NOW
Greetings from the CPDD Awards for Excellence Committee!

Our committee is privileged to administer the Nathan B. Eddy Memorial Award, the Marian W. Fischman Lectureship Award for An Outstanding Woman Scientist, the Mentorship Award, the Joseph Cochin Young Investigator Award, the J. Michael Morrison Award (not offered in 2023), the Innovator Award (not offered in 2023) and the newly established Mary Jeanne Kreek Underserved Populations Award.

We are pleased to congratulate the winners of the 2023 CPDD Awards for Excellence:

**Mary Jeanne Kreek Underserved Populations Award:** Denise Hien, Ph.D., Rutgers University  
**Nathan B. Eddy Memorial Award:** Edythe London, Ph.D., UCLA  
**Marian W. Fischman Lectureship Award:** Joy Schmitz, Ph.D., UT Health Houston  
**Mentorship Award:** Dace Svikis, Ph.D., Virginia Commonwealth University  
**Joseph Cochin Young Investigator Award:** Justin Strickland, Ph.D., Johns Hopkins University School of Medicine

Please join us in congratulating our colleagues for their outstanding achievements!

Our committee would like to again remind the membership that we are committed to a confidential, yet transparent, review process. The committee members are required to disclose actual or perceived conflicts of interest with any of the nominees--those with conflicts do not participate in the review process for a given award. Committee members not in conflict are provided the confidential materials for each nominee, and asked to give preliminary scores, which are then used to guide the review discussion. Merit is the primary criterion, but diversity is encouraged and embraced. We would also like to remind everyone of some important nomination rules: individuals can only nominate one person for an award but are permitted to submit nominations for more than one award; the same person cannot be nominated for more than one award in the same year; and Awards for Excellence Committee members are not allowed to be nominated for an award. Thank you for keeping these restrictions in mind when considering potential nominees for next year’s awards.

I am honored to continue to serve as the Chair for the Awards for Excellence Committee and look forward to working with the Committee and the College to recognize the best and brightest of our members in the coming years. Please consider nominating deserving colleagues for one or more of the CPDD Awards for Excellence next year, and/or making award donations.

---

**Spring 2023  
In Memoriam**

CPDD celebrated the lives and accomplishments of our distinguished members. Please join us in celebrating the lives of those we lost since our last issue.

Robert Brooner, Ph.D.  
Mary E. Abood, Ph.D.

Read their memorials by clicking [here](#).
2023 Travel Award recipients received complimentary registration to the 2023 Annual Meeting and are eligible to apply for the same award in the future (excluding the Holtzman and Primm-Singleton).

9th Annual Steve G. Holtzman Travel Award for Preclinical Investigators
- Tanya Pareek, MS, University of Mississippi Medical Center
- Yasmim Serra, PhD Student, Universidade Estadual de Santa Cruz, Ilhéus, BA, Brazil
- Ghazaleh Soleimani, PhD, Amirkabir University of Technology

CPDD International Award
- Shelley Edwards, BS, National Institute on Drug Abuse, Intramural Research Program
- Alyssa Falise, PhD Student, University of Florida
- Karli Hochstatter, MPH, PhD, Friends Research Institute

Primm-Singleton Minority Travel Award
- Skye Bristol, B.S., University of South Florida
- Kanila Brown, MA, MS, University of Missouri- St. Louis
- Bria-Necole Diggs, BS, University of Miami Miller School of Medicine
- Diamond Meadows, MSW, East Tennessee State University
- Quynh Vo, BS, University of California Los Angeles, Department of Family Medicine

CPDD Early Career Investigator Awards
- Katrina Prior, PhD, The University of Sydney
- Thomas Arkell, PhD, Centre for Human Psychopharmacology, Swinburne University of Technology
- Sydney Batchelder, PhD, University of Vermont
- Alexandria Bauer, PhD, Rutgers University
- Devika Bhatia, MD, University of Colorado School of Medicine
- Madeline Frost, MPH, PhD, University of Washington School of Public Health, Department of Health Systems & Population Health
- Neo Gebru, PhD, Brown University
- Sergej Grunevski, BS, Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick
- Alexandre Guerin, PhD, University of Melbourne
- Patrick Hibbard, PhD, Oregon Social Learning Center
- Kwang-Hyun Hur, PhD, McLean Hospital, Harvard Medical School
- Robert Kohler, PhD, Yale University School of Medicine
- Ofir Livne, MD, Mailman School of Public Health, Columbia University
- Zachary Mannes, MPH, PhD, Columbia University, Mailman School of Public Health
- Olivia Marcus, MPH, PhD, New York University
- Paola Mattey Mora, PhD, Indiana University - School of Medicine
- Li Yan McCurdy, PhD, Yale University School of Medicine
- Laura Murray, PhD, McLean Hospital/Harvard Medical School
- Courtney Nordeck, PhD, Friends Research Institute
- Matthew Novak, Ph.D, Johns Hopkins University School of Medicine
- Henrique Oliva, MD, PhD, Yale University School of Medicine
- Broc Pagni, PhD, New York University
- Juan G Perez-Carreno, MD, University of Florida
- Huyen Pham, PhD, Semel Institute - UCLA
- Sean Regnier, PhD, University of Kentucky, College of Medicine
- Yasna Rostam Abadi, MD,MH, NYU School of Medicine
- Mark Rzeszutek, PhD, University of Kentucky, College of Medicine
- Clara Sancho-Domingo, MA, Miguel Hernández University
- Thomas Santo, MPH, PhD, National Drug & Alcohol Research Centre, UNSW Sydney
- Madison Wright, BSc, University of Toronto
NIDA Women & Sex/Gender Junior Investigator Travel Awards
- Breanne Biondi, BA, MPH, Boston University School of Public Health
- Jordan Carter, BS, Department of Neuroscience, Medical University of South Carolina
- Brooke Christensen, BS, Vanderbilt University
- Robyn Ellis, PhD, McLean Hospital - Harvard Medical School
- Nia Fogelman, PhD, Yale University School of Medicine
- Villisha Gregoire, BSc, PhD, Michigan State University
- Eric Harrison, BS, Pennsylvania State University
- Percell Kendrick, BS, University of Kentucky, College of Medicine
- Myla Lyons, BA, University of Michigan/VA Ann Arbor Healthcare System
- Stephanie Mallahan, MPH, University of Arizona, College of Medicine
- Justin Matheson, PhD, Centre for Addiction and Mental Health
- Kathleen McNealy, MA, University of Nebraska
- Sanjana Mitra, BSc, MPH, PhD, Centre on Drug Policy Evaluation
- Alexandra Palmisano, PhD, Yale University School of Medicine
- Maryam Sorkhou, BSc, University of Toronto and CAMH
- Sienna Strong-Jones, BA, Department of Human Development and Family Studies, Pennsylvania State University
- Martha Tillson, BA, MA, PhD, University of Kentucky
- Anna Wiese, BA, BS, Virginia Commonwealth University
- Yitong Xin, MBA, MSW, The Ohio State University
- Shawn Flynn, MS, University of Texas Health Science Center at San Antonio
- Tanya Pareek, MS, University of Mississippi Medical Center

NIDA Directors Travel Awards
- Julia Brooks, MA, University of Illinois At Chicago
- Ashley Dowd, PhD, Johns Hopkins School of Medicine
- William Eger, MPH, University of California - San Diego
- Angela Estadt, MPH, College of Public Health, The Ohio State University
- Brett Gelino, PhD, Department of Psychiatry, Johns Hopkins University School of Medicine
- Sarah Goldsmith, BS, Medical University of South Carolina
- Priscila Gonçalves, PhD, Columbia University
- Pooja Lagisetty, MD, University of Michigan
- Natasha Ludwig-Barron, MPH, PhD, Department of Medicine, Division of Prevention Science, University of California, San Francisco
- Megan Marziali, BSc, MPH, Columbia University Medical Center
- Greer McKendrick, PhD, Johns Hopkins School of Medicine
- Katharine Nelson, PhD, Medical University of South Carolina
- Azizi Ray, PhD, PharmD, University of Arkansas for Medical Sciences
- Vanessa Serrano, BA, University of California, San Diego
- Anjalee Sharma, MSW, Friends Research Institute
- Benjelene Sutherland, MS, Florida International University
- Eleanor Towers, BS, University of Virginia
- Rhiannon Wiley, MA, University of Vermont
- Carlos Zamarripa, PhD, Johns Hopkins University School of Medicine, Department of Psychiatry
- Madison Marcus, BA, Dept. Pharmacology/Toxicology, Virginia Commonwealth University
Day-to-Day Work

What are your publishing goals and how do you achieve them?
When I left my postdoc in 2011 I decided to shift from the traditional path in academia into a career in medical writing. So for many years, writing and publishing have been the most critical part of my career (and are now the cornerstone of my consulting business BAK and Associates). Over the past 10+ years, I have maintained a publishing record in scholarly journals while also writing for the popular press. My current publishing goals focus on aging, tobacco use, and other substance use, as well as the inclusion of people with lived experience in research design and dissemination. I have three publications I am working on for academic journals looking at tobacco use and perceptions among adults 65 years and older. Older adults are often overlooked in research and policy that is focused on substance use – in particular smoking. I think that one reason for this gap is the prioritization of prevention in younger people to the exclusion of older cohorts. This bias has to change as the number of older adults is going to more than double in the coming decades and there are signs that there is an increase in the rate of SUDs in older populations. In addition, I am working on a manuscript focused on how people with lived experience using nicotine/tobacco can be part of the research design process in order to improve the rigor of research, reduce stigma, and empower the general public (not just traditionally trained scientists) to be part of the scientific process. I plan to write about each of these academic publications for the popular press.

Long-Term Career

In the short-term, we all want to get grants and publish papers, but what do you/did you consider as your long-term career goals? (e.g. tenure, editor positions, directorship positions?)
My long-term career goals are to write about substance use research and policy for the general public in a way that not only informs them but engages them closely with the topics I cover. I think that our work in academia and our publications are important, but most of it is relegated to paywalled journals or scientific conferences that are not attended by the public. I want to refine my writing so that it is engaging and tells a story. I have taken a class in creative nonfiction to help me improve my storytelling skills to reach a broader audience. My primary goal is to improve the quality and reach of science, and I think I can do that best by writing for fellow scientists and the public.

Work/Life Balance

In your experience, when is a better time to start a family? Should it be after you graduate, after completion of a post-doctoral fellowship, after completion of few years of first faculty position, or perhaps some other time?
I don’t think there is a perfect time. Best you can do with decisions like getting married, starting a family, when to buy a house etc. is make the best choice you can at that time and roll with it as life evolves. If starting a family is your priority, you can make it happen even if money or time is insufficient. This also goes for other life choices like finally taking that 3 week backpacking trip to Vietnam (DO IT!) or taking a leave of absence to be with a family member dealing with life-threatening health issues. Life does not wait as we finish our postdocs, tenure, etc. I think the best approach is to work hard at reaching your career goals while making the bigger life goals equally important. I tried so hard to be strategic with these choices when I was in grad school and starting my postdoc. Getting married, buying a house, and all those decisions became more of a checklist than something I truly wanted. All that planning suddenly shifted in the first few months of my postdoc due to a family crisis. Something I hadn’t planned completely postdoc. Getting married, buying a house, and all those decisions became more of a checklist than something I truly wanted. All that planning suddenly shifted in the first few months of my postdoc due to a family crisis. Something I hadn’t planned completely undid all the obsessive planning I had done over starting a family and related life goals. Since that reset, I have found that being
more flexible with my life timeline is best for me. And now, as a woman in her early 40s, I feel confident I made the right
decisions at the right time around deciding to have a family or other life choices. I am not sure I would feel this confident if I had
pushed the very tight timeline I had imagined for myself in my 20s that was very much connected to career stages like getting a
faculty position.

Overcoming Adversity

**Was there a time in your career that you found particularly difficult, and how did you get through it?**
Some of the most challenging times in my career have been when I have worked for someone or an organization that only hired
me to support their own advancement. This means that my unique skills, research interests, or career goals were overlooked and
sometimes criticized. This has happened a couple of times during my career, and it can be quite demoralizing and result in a
tremendous amount of self-doubt. There is a tension between doing work for the good of the team (or lab or company or boss)
versus building your own career and independent expertise. Ultimately I saw that these situations were unhealthy, and I was able
to move on and find collaborative work where I could contribute to the team but also have my own agency and ownership of
projects. This is one reason I created my own freelance consulting business, BAK and Associates. It has allowed me to thrive as an
independent thinker while also continuing collaborations with trusted colleagues.

Advice for Young Investigators

**What would you recommend to people who have a fear of missing out on all of the great conferences and presentations? How many
conferences a year should one strive to attend?**
My best advice for conferences is to have one that you attend each year where you can build your “science family”. That is how I
feel about CPDD and I really look forward to catching up with everyone during the annual conference. It’s always a very positive,
motivating experience to see what colleagues are doing and to build new research collaborations. I also recommend you pick one
conference a year that is totally new to you so you can learn about new ways of looking at science and new communities of
researchers. This approach pushes you out of your comfort zone and I think will help you be a more thoughtful scientist that can
look at the same issue from different perspectives. My next goal is to attend a geriatric conference where I can share some
substance use research with people that may not otherwise think about this topic in the context of aging.

For the Full
2023 CPDD ANNUAL MEETING SCHEDULE

CLICK HERE
VISIT CPDD.ORG TO
SHARE YOUR WORK
SHARE NOW
Sherry McKee, PhD, DADR Associate Editor


Author Summary: The true prevalence of opioid use disorder (OUD) in the United States (US) is unknown. Survey and administrative data sources provide some estimates, but their generalizability is limited and biases abound. We used classical epidemiological techniques to provide new estimates of the number of people with OUD in the United States. First, we estimated OUD in the National Survey on Drug Use and Health (NSDUH), and based on existing capture-recapture studies, multiplied prevalence by 4.5x. Second, we estimated the probability of drug poisoning death among people with OUD (meta-analysis indicates 0.52/100,000), and divided the number of drug poisoning deaths in the US by this probability. Estimates were weighted to account for increase in drug-related mortality in recent years due to fentanyl. We estimate that approximately 6.7 to 7.6 million adults in the US are currently living with OUD. These estimates underscore the unmet need for capacity building around services for individuals with OUD that are urgently needed.

Editor justification: Rates of opiate use disorder and risk of overdose continue to be a significant public health concern, particularly as the US drug supply has become increasingly dangerous with the proliferation of fentanyl. The paper by Dr. Katherine Keyes and colleagues provides critical information regarding the current prevalence for opioid use disorder, necessary to inform national policy.

Teri Franklin, PhD, DADR EiC


Study Summary: Excessive alcohol and tobacco use are risk factors for poor health in both men and women, but use patterns and relationships with diseases and mortality differ between sexes. One possible index of the effects of substance use on overall health is epigenetic aging as assessed by DNA methylation
profiles. This study assessed the sex-specific effects of individuals’ alcohol and tobacco use, as well as paternal alcohol and paternal/maternal tobacco use, on their children's cellular aging as measured by four different measures of epigenetic age acceleration. We found that current or former tobacco smoking were associated with epigenetic age acceleration with sex-specific effects. Additionally for females drinking alcohol was associated with epigenetic age acceleration. When looking at the long-term effects of alcohol use on offspring, paternal heavy alcohol use when children were 12 or younger was associated with epigenetic age acceleration when the children were adults. Thus, there are sex-specific effects of alcohol and tobacco use, as well as paternal heavy alcohol use, on epigenetic age acceleration.

Editor justification: This study brings to light important knowledge regarding the effects of alcohol and tobacco use on epigenetic age acceleration, and makes me hungry for more. In particular, as shown by the authors, paternal heavy alcohol use was associated with a 4 and ½ year increased epigenetic age acceleration among offspring (as adults) while heavy alcohol use in and of itself, does not directly influence the epigenome of the offspring. The authors point out that future studies are warranted to understand mediation factors (i.e., psychosocial stressors).

Teresa Franklin, PhD, DADR EiC


Article Summary: Xylazine, a veterinary tranquilizer, is often present in heroin/fentanyl in Philadelphia and is increasingly found elsewhere. To explore how people who use heroin/fentanyl in Philadelphia feel about xylazine adulteration, we analyzed interviews with people who use drugs during interviews about their fentanyl test strip practices. The topic of xylazine arose in 13 out of 29 interviews. Among these 13, participants believed they were frequently exposed to xylazine when intending to use solely heroin/fentanyl and unanimously voiced disliking the presence of xylazine in their drugs. In addition to disliking the feeling of the xylazine and heroin/fentanyl combination, they described long periods of sedation accompanied with memory loss. Several voiced safety concerns related to heavy sedation after use and noted complications with treating withdrawal from xylazine and an opioid. Participants indicated a desire to obtain and use xylazine test strips, the technology for which did not exist at the time of interviews. Many indicated they would prefer those test strips over fentanyl test strips to avoid xylazine exposure. A xylazine test strip may have the potential to positively impact drug use in a similar manner to fentanyl test strips, especially if accompanied with risk reduction communication.

Editor justification: It always piques my interest when findings oppose what we generally consider to be truth. This is an eye-opener and important information as the problem of xylazine-adulterated heroin is sweeping our nation. https://nypost.com/2023/02/21/skin-rotting-drug-tranq-infiltrates-big-cities-zombifying-bodies/"

**Study Summary:** We identified interpretable, multidimensional subgroups who were prescribed medication for opioid use disorder (MOUD) in substance use treatment programs in the US (using TEDS-A data, N=740,015) but who were not represented or were under-represented by clinical trial participants (using 3 harmonized comparative effectiveness trials for MOUD that are part of the NIDA CTN, N=2,199).

Excluding pregnancy as a subgroup-defining characteristic, 8.3% of those treated with MOUD in TEDS-A were not represented at all in any of the clinical trials, and 44% were underrepresented. Under-represented subgroups were dominated by non-Hispanic Black individuals who were older, never married, with lower-levels of education, and who reported no past-30-day use of amphetamines, benzodiazepines, nor cannabis. In general, older age was a common feature of non-represented and under-represented subgroups despite age not being a reason for exclusion in any of the trials. This is an increasingly relevant subpopulation, as the number of older adults entering MOUD treatment tripled 2007-2017, and the number of older adults with opioid-related emergency department visits quadrupled over the same period. By characterizing subgroups who initiate MOUD treatment but who are under-represented in trials, we hope to support better accountability for representation and inform targeting for future trial recruitment.

**Editor’s Rationale:** I thought the authors of this study did a nice job of quantifying a potential source of health outcome inequality in addiction treatment. It is important that participants in clinical trials reflect the characteristics of patients who will ultimately receive the treatment. In the era of personalized medicine, it is becoming increasingly clear that these types of demographic characteristics can impact how well a treatment works. This paper shows that a course adjustment is needed to improve consilience between participants in clinical trials for addiction treatments and people who will actually receive those treatments in the clinic. I also appreciated the authors’ clever use of multiple preexisting data sources to draw these comparisons.
One paper worthy of note describes outcomes in an exciting area of addiction science that is beginning to yield knowledge on heritability of addictive disorders. In their report, Min et al., present findings on mortality and substance use histories of the progeny through age 12 from a prospective birth cohort of women who were exposed to cocaine while pregnant in the mid-1990s. A notable strength to this report reflects the use of comprehensive, multidisciplinary developmentally appropriate measures and the high rate of retention of the women and their children. Findings show with precision the significant role for involvement with marijuana in adolescence to indirectly lead to substance use disorders in adulthood in this sample of children with prenatal cocaine exposure. Findings also highlight modifiable and non-modifiable factors during childhood development that might correspond with differences in outcomes measured for children with prenatal cocaine exposure.

As the overdose crisis globally continues to increase, the availability and timely access to data describing the kinds of outcomes one can expect from different types of treatments for opioid use disorder grows in relevance. In their “birth paper,” Sugarman et al., describe the development and implementation of an interactive evidence map that produces easy-to-read, accurate and current outcomes synthesizing the evidence regarding specific medications for opioid use disorder. The authors note that while this evidence map is not a meta-analysis or systematic review, the process in constructing the evidence map is similar. A pleasant feature of the evidence map is its ease of use. If you click on the link to the landing page for the evidence map (https://app.prism.bio/p/1/nyulhoudevidencemap), you will land at the dashboard for the evidence map that is both intuitive and comprehensive. The coverage of the papers included in the evidence map is impressive. The work of this team is laudable in its effort to increase quality of care and research by increasing ease of access to the evidence base on treatments for opioid use disorder.

Prenatal Cocaine Exposure and Substance Use Disorder in Emerging Adulthood at Age 21

Meeyoung O. Min, Sonia Minnes, Sun-Kyung Kim, June-Yung Kim, Lynn T. Singer
doi.org/10.1016/j.drugalcdep.2022.109736

This birth cohort prospective study examined the association of prenatal cocaine exposure (PCE) with substance use disorder (SUD) in emerging adulthood, and whether childhood externalizing behaviors and adolescent substance use mediated the relationship. Participants were 367 (187 PCE; 53% female) adults at age 21, primarily urban African American, recruited at birth. About 45% of the sample were determined as having at least one SUD. PCE was related to greater externalizing behaviors at age 12 and substance use, mainly marijuana, at age 15, which were associated with SUD at age 21, suggesting PCE-related impairment in behavioral disinhibition persisting to emerging adulthood.
Opioid Use Disorder Treatments: An Evidence Map

Allison Sugarman, Alexandria Vittitow, Anna Cheng, Mia Malone, Ryan McDonald, Nancy Pace, Ololade Williams, Babak Tofighi, Jennifer McNeely, Daniel Schatz, Timothy Roberts, Spencer Phillips Hey, Kathleen Garrity, Kristin Lindquist, Joshua D. Lee
doi.org/10.1016/j.drugalcdep.2022.109657

This opioid use disorder evidence map aims to provide an interactive display of all peer-reviewed trials assessing the treatment of OUD and clinically relevant outcomes. Through 2020 and with updates to follow, the most well-examined OUD interventions were methadone, buprenorphine, and naltrexone, and the most common outcomes were heroin/opioid use, retention in treatment, and non-opioid drug use. Clear gaps included alternative opioid agonist treatments and overdose as a clinical outcome. The map allows users to quickly locate a given intervention-outcome intersection, overlay filters for study design, sample size, year, region, and funding source, and download the resulting cluster of citations.

Authors of the DADR Editor Picks will highlight their work in a CPDD-sponsored Webinar to be held virtually on May 17, 2 PM EST (11 AM PST, 1 PM CST). Enjoy the research presentations over your lunch. More details to come!

Spring 2023
Communications Committee Report
Chair: Annie Kleykamp, Ph.D.

The Communications Committee is implementing several initiatives to communicate substance use research findings. Efforts include the production of Newsline by Editor Dr. Maria Parker and reviewing submissions to the News and Views section of Drug and Alcohol Dependence. News and Views submissions can be submitted by CPDD members to our committee (Dr. Barrett Montgomery is the News and Views Editor). Submissions should be focused on new advances in substance use research and the promotion of activities of CPDD. Last year the committee updated the instructions for News and Views submissions, including a limit of 2,500 words and the requirement that all submissions be reviewed by two committee members and the CPDD Executive Committee. Be on the lookout for a special call for News and Views submissions related to high-profile substance use and addiction topics in the coming month.

In addition, the committee has worked to increase Twitter engagement, including a new option for members to submit research [AK1] they would like profiled on the CPDD Twitter handle. An updated Media Forum was developed and accepted as a workshop for the 2022 CPDD Annual Conference that will again be shared during the 2023 conference in collaboration with CPDD member, Dr. Jonathan Stoltman, of the Opioid Policy Institute and Reporting on Addiction. The Forum is focused on helping attendees learn best practices in science journalism, including pitching stories to editors and general science writing.

The committee is also working to develop a webinar addressing lived experience and stigma in substance use research. The committee will plan these efforts during bi-monthly meetings throughout 2023. If members are interested in proposing potential topics for webinars or News and Views submissions, please reach out to Dr. Annie Kleykamp (akleykamp@gmail.com).
Early Career Member Committee (ECMC) Committee Report
Chair: Danielle Davis, PhD

The Early Career Member Committee (ECMC) is dedicated to serving the needs of early career investigators involved with CPDD. We are looking forward to our upcoming conference programming.

Our annual workshop “Navigating a Career in Addiction Science” was accepted for this year’s CPDD conference and we are thrilled to be able to present this workshop again for ECMC members and other early career investigators. We have speakers from across academia, industry, and government discussing their experiences and the workshop is co-chaired by Dr. Denise Vidot, who developed the first iteration of this workshop, and the ECMC chair Dr. Danielle Davis.

Our committee has also been meeting to plan this year’s Annual Mentorship Program and our ECMC Poster Competition. The Mentorship Program is a longstanding program by our committee which pairs mentors and mentees at the Annual Conference. This year we are revising the interest survey for this program to improve mentor-mentee matches. The Poster Competition is in its third year and will award two predoctoral and two postdoctoral fellows that have exceptional posters with a $250 cash prize. This competition requires the fellows to develop a “flash” presentation on their poster prior to the conference which is judged by expert in the field.

Additionally, we are excited to work with other committees in the future to develop programming to serve the early career population of CPDD, a population that represents the future of the Addiction science field and the CPDD Society.

Travel Awards Committee Report
Chair: Stephen Kohut, PhD

The CPDD Travel Awards Committee received a total of 241 submissions for travel awards to attend the 2023 meeting - almost 30 more applications than last year. We received 106 applications for 30 CPDD Early Career Investigator Travel Awards, 46 applications for 3 FORCE Travel Awards, 39 applications for 20 NIDA Director’s Travel Awards, 39 applications for 20 NIDA Women and Sex/Gender Travel Awards, and 11 applications for 1 Holtzman Travel Award for Preclinical Investigators. It's great to see so much growing interest from young investigators in the field of drug abuse. Award notifications are expected to go out in early March.

We are putting together another great line-up for the always popular Brunch with Champions this year. The Brunch, which is typically held on the last day of the annual meeting, is a great opportunity for pre-docs, post-docs, and junior faculty to chat informally with senior investigators in the field of drug abuse research. Attendance is limited to people who have received their terminal degree within the last 10 years and are at or below the rank of Assistant Professor (or equivalent). Seating is limited so be on the lookout for registration details later this Spring.
Committee Updates

Spring 2023

International Committee Report
Chair: Laura Brandt, PhD

The International Committee (IC) is excited to announce that our workshop proposal entitled, “A View beyond the Horizon: Innovative Methodologies and Approaches in Substance Use Disorder Research and Treatment Utilized Internationally” was accepted for the 85th Annual Scientific Meeting of the CPDD. The workshop has been scheduled for 6/17/2023, 3-4:30pm, Mountain Time Zone. We are looking forward to welcoming you to this exciting forum, with presentations from Eugenia Oviedo-Joekes, Thiago Fidalgo, Min Zhao and Suzanne Nielsen providing insight into methodological and treatment innovations from international contexts.

In addition to the workshop, the IC aims to host a networking zone at the 2023 CPDD meeting for international participants and US-based researchers who are interested in international exchange and collaboration. This networking zone is meant to provide opportunities for “match making” (i.e., finding collaborators for international research projects) and exchanging experiences with international research, as well as providing information and guidance for early career researchers on fellowship opportunities (i.e., NIDA INVEST and Humphrey fellowships).

The NIDA International Forum will again be held virtually on June 8-9, 2023. The IC will participate in the NIDA International Forum/CPDD Workshop International Research Poster Session and select the “Best Poster” recipient.

Finally, the IC continues to advocate for means that would lower the potential cost of Low- and Middle-Income Country (LMIC) participation in CPDD meetings. If you are looking for opportunities – either for yourself or colleagues – to stay at more reasonably priced housing during the 2023 meeting, please do not hesitate to reach out to the members of the International Committee. We would be happy to act as a “liaison,” assisting LMIC participants in finding more affordable housing options and connecting participants for room sharing options.

Spring 2023

Long-Range Planning Committee (LRPC) Report
Chair: William Stoops, PhD

The Long-Range Planning Committee (LRPC) meets virtually once per month. Members are Bill Stoops (Chair), Alan Budney, Ziva Cooper, Rich De La Garza, Linda Dwoskin, Shereece Fields, Jermaine Jones, Stacey Sigmon, Eric Strain and Sharon Walsh. Since the June 2022 meeting, the LRPC has focused on ensuring progress of the strategic plan (fully approved by the Board of Directors in February 2022). In partnership with Parthenon Staff, a dashboard has been developed that tracks strategic plan initiatives; any problems identified through that dashboard are discussed by the LRPC and brought to the CPDD Executive Committee for resolutions. Other LRPC activities since June 2022 have included: 1) discussion of and feedback on CPDD task force activities including the NIH Funding Inequity Task Force, the Education Task Force (which has resulted in appointment of an Education Committee), the Mentorship Task Force and the LGBTQIA+ Task Force, 2) support of the UE-5 Mosaic application that was submitted in partnership with the American College of Neuropsychopharmacology and 3) working with Parthenon to create short descriptions of five strategic plan initiatives.
Membership Committee Report  
Chair: Erin McClure, PhD

The Membership Committee continues to work to promote membership in the college and to improve processes for interested individuals to obtain membership. We are pleased to announce that after the removal of the sponsor letter requirement for CPDD membership applications, the number of applicants increased substantially. We have received a record number of membership applications in late 2022 and early 2023. We are pleased to see that highly qualified applicants are applying for membership in the college and hope this will continue.

We continue to be committed to retaining members in the college and ensuring that members-in-training (MITs) transition to Associate or Regular membership and that we don’t lose our early career members. Also, we are interested in trainees who attend the CPDD meeting but do not apply for MIT status and/or Associate and/or Regular membership as they advance in their careers. We are working with the Early Career Members Committee (ECMC) to ensure our efforts are not duplicated across committees and we can contribute efforts towards this common goal. We wish to better understand the barriers that prevent applying for membership at all levels and transitioning to the next level of membership, when appropriate.

Additionally, we are focusing efforts on advertising CPDD membership and the annual meeting to related, diverse organizations that have typically been underrepresented in our college. We plan to formalize our membership drives and forge new connections with organizations and groups that can spread the word about CPDD. We will continue to work closely with the underrepresented populations (URPOP) committee to accomplish our shared goals of improving representation in CPDD.

Our committee continues to promote membership in the college and attract new members, but as always, we need your assistance to spread the word about the benefits of CPDD membership within your professional networks and among your trainees. Helping the Membership committee to promote and encourage new member applications is always appreciated!

Human Research Committee Report  
Chair: Omayma Alshaarawy, PhD

Since the last update, the committee requested feedback from CPDD members on previous forums, and topics of interest for future discussion/action. Based on the responses, the committee submitted an abstract for its annual forum titled “Nothing About Us Without Us: Engaging Individuals with Lived Experience of Substance Use Disorders in Substance Use Research Development and Implementation”. The forum was accepted by the CPDD program committee. It is co-chaired by Drs. Omayma Alshaarawy and Rachel Luba, and Drs. Noel Vest, Tessa Frohe and Manesh Gopaldas are scheduled to present.
Membership
Applications Deadline
March 31, 2023
REFER A COLLEAGUE